- Home
- All Stock List
- BSE
- Gufic BioSciences Ltd Share Price
Gufic BioSciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap
348.05
-1.80 (-0.51%)
-
Underperforms Index
16.83%
Return (1Y)
Underperformed BSE Healthcare by 3.83%
-
More Volatile
2.87%
Standard Deviation (1Y)
Higher than BSE Healthcare by 1.81%
-
Not so consistent
6/12
Months
underperformed BSE Healthcare
-
AxisDirect View
No View
501
278
News & Announcements
-
Gufic BioSciences standalone net profit declines 13.21% in the December 2024 quarter
15 - Feb - 2025 12:00 | 66 days ago
Net profit of Gufic BioSciences declined 13.21% to Rs 19.32 crore in the quarter ended December 2024 as against Rs 22.26 crore during the previous quarter ended December 2023. Sales rose 2.98% to Rs 207.79 crore in the quarter ended December 2024 as against Rs 201.78 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 207.79 201.78 3 OPM % 16.34 18.07 - PBDT 30.90 33.70 -8 PBT 26.28 29.56 -11 NP 19.32 22.26 -13 Powered by Capital Market - Live News
-
Gufic BioSciences to announce Quarterly Result
73 days ago
-
Gufic Biosciences tumbles after Q2 PAT drops 6% YoY to Rs 22 cr
18 - Nov - 2024 12:00 | 155 days ago
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.
Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
Powered by Capital Market - Live News
-
Gufic BioSciences to announce Quarterly Result
73 days ago
-
Gufic Biosciences tumbles after Q2 PAT drops 6% YoY to Rs 22 cr
18 - Nov - 2024 12:00 | 155 days ago
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.
Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
Powered by Capital Market - Live News
-
Gufic Biosciences Q2 PAT drops 6% YoY to Rs 22 cr
158 days ago
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.
Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
The scrip rose 1.95% o settle at Rs 446.65 on Thursday, 14 November 2024, the domestic stock market to remain closed today on account of Guru Nanak Jayanti.
Powered by Capital Market - Live News
-
Gufic BioSciences standalone net profit declines 13.21% in the December 2024 quarter
15 - Feb - 2025 12:00 | 66 days ago
Net profit of Gufic BioSciences declined 13.21% to Rs 19.32 crore in the quarter ended December 2024 as against Rs 22.26 crore during the previous quarter ended December 2023. Sales rose 2.98% to Rs 207.79 crore in the quarter ended December 2024 as against Rs 201.78 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 207.79 201.78 3 OPM % 16.34 18.07 - PBDT 30.90 33.70 -8 PBT 26.28 29.56 -11 NP 19.32 22.26 -13 Powered by Capital Market - Live News
-
Gufic BioSciences to announce Quarterly Result
73 days ago
-
Gufic Biosciences tumbles after Q2 PAT drops 6% YoY to Rs 22 cr
18 - Nov - 2024 12:00 | 155 days ago
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.
Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
Powered by Capital Market - Live News
-
Gufic Biosciences Q2 PAT drops 6% YoY to Rs 22 cr
158 days ago
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.
Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
The scrip rose 1.95% o settle at Rs 446.65 on Thursday, 14 November 2024, the domestic stock market to remain closed today on account of Guru Nanak Jayanti.
Powered by Capital Market - Live News
-
Gufic BioSciences standalone net profit declines 13.21% in the December 2024 quarter
15 - Feb - 2025 12:00 | 66 days ago
Net profit of Gufic BioSciences declined 13.21% to Rs 19.32 crore in the quarter ended December 2024 as against Rs 22.26 crore during the previous quarter ended December 2023. Sales rose 2.98% to Rs 207.79 crore in the quarter ended December 2024 as against Rs 201.78 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 207.79 201.78 3 OPM % 16.34 18.07 - PBDT 30.90 33.70 -8 PBT 26.28 29.56 -11 NP 19.32 22.26 -13 Powered by Capital Market - Live News
-
Gufic BioSciences to announce Quarterly Result
73 days ago
-
Gufic Biosciences tumbles after Q2 PAT drops 6% YoY to Rs 22 cr
18 - Nov - 2024 12:00 | 155 days ago
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.
Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
Powered by Capital Market - Live News
-
Gufic BioSciences to announce Quarterly Result
73 days ago
-
Gufic Biosciences tumbles after Q2 PAT drops 6% YoY to Rs 22 cr
18 - Nov - 2024 12:00 | 155 days ago
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.
Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
Powered by Capital Market - Live News
-
Gufic Biosciences Q2 PAT drops 6% YoY to Rs 22 cr
158 days ago
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.
Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
The scrip rose 1.95% o settle at Rs 446.65 on Thursday, 14 November 2024, the domestic stock market to remain closed today on account of Guru Nanak Jayanti.
Powered by Capital Market - Live News
Stock Trivia
MF shareholding in Gufic BioSciences Ltd has increased by 16.32% since past 3 Months
MF shareholding in Gufic BioSciences Ltd has increased by 63.12% since past 1 Year
MF shareholding in Gufic BioSciences Ltd has increased by 16.32% since past 3 Months
FII shareholding in Gufic BioSciences Ltd has increased by 170.56% since past 1 Year
MF shareholding in Gufic BioSciences Ltd has increased by 63.12% since past 1 Year
MF shareholding in Gufic BioSciences Ltd has increased by 16.32% since past 3 Months
MF shareholding in Gufic BioSciences Ltd has increased by 63.12% since past 1 Year
